MedTrace Logo

Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)

NCT06813365 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 190

Last updated 2025-12-30

No results posted yet for this study

Summary

This study is designed to evaluate safety and antitumor activity of DZD6008 in patients with advanced NSCLC with EGFR mutations. This is the first time the drug is tested in human.

Conditions

  • Nonsmall-cell Lung Cancer

Interventions

DRUG

DZD6008

Daily dose of DZD6008

Sponsors & Collaborators

  • Dizal Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-12
Primary Completion
2026-12-30
Completion
2028-07-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06813365 on ClinicalTrials.gov